

Deep-sea bacteria inspire researchers to develop new ways to see, treat tumours

A new compound that mimics the light processing capabilities of deep-sea bacteria could help surgeons "see" tumours during operations, while also serving as a photosensitizing agent in photodynamic therapy.

READ MORE >

TFRI-funded researchers uncover "evolutionary arms race" between cancer and immune system

A study led by TFRI-funded researchers has revealed how deadly ovarian cancer cells escape the immune system, setting the stage for a better understanding of how and why patients respond to promising immunotherapy treatments.

READ MORE >



Co-targeting EphA2/A3 reduces rGBM tumour growth in mice models

A bi-specific antibody created by a TFRI-funded team in Ontario has shown great promise in reducing tumour growth in patients with recurrent glioblastoma, a deadly disease with no known cures.

READ MORE >

How do doctors really feel about active surveillance?

A study asking health care professionals why many men with low-risk prostate cancer opt against active surveillance reveals that both doctors and patients need better information for decision making.

READ MORE >



Discovery of CD33 in human cord blood cells may affect design of targeted AML therapies

A team of TFRI-funded researchers reveals why some trials that have used CD33 as a potential target for AML therapies have shown specific toxicities expected from a loss of normal stem cells.

READ MORE >

Scientists make oncolytic virus more effective with help from protein found in mosquito virus

By using a protein from a virus first found in mosquitoes in Japan nearly 70 years ago, TFRI-funded researchers have helped a known oncolytic virus bypass the RNA interference pathway.

READ MORE >

BC-based team answers long-held question about myelodysplastic syndromes

A new study explains why the loss of two microRNAs can push people with MDS to develop two seemingly opposite conditions: bone marrow failure and acute leukemia.

READ MORE >



Team identifies CDC25 as a common therapeutic target for triple-negative breast cancer

Targeting CDC25 could bring hope to patients with RB1-deficient triple-negative breast cancer (TNBC), according to a Toronto-based TFRI-funded team.

READ MORE >

Other TFRI News

Terry Fox Run Challenge 2018: Join us Sunday, Sept. 16 by running or walking in your local run >

TFRI's Scientific Committee on Research Excellence (SCORE) shortlists applicants for 2019 PPG competition site visits >

TFRI launches second pilot program for pan-Canadian precision medicine network with creation of Montreal Cancer Consortium >

Joint BC Cancer/Princess Margaret Cancer Centre pilot project team TF4CN reports steady progress >

2018 PPG holders receive $13 million to solve key cancer challenges >

Mark your calendars: Quebec Node Science Day on Oct. 11, BC Cancer Summit with talks by TFRI researchers on Nov. 23 and 24 and TFRI-Ontario Node Day on Dec. 10 >

TFRI senior advisor Darrell Fox and 22 other riders pedal 360km in a day, raising $50K for cancer research >

Links is compiled and circulated quarterly by TFRI to highlight recently published research by our funded investigators. It is produced by TFRI HQ in Vancouver, BC. TFRI is either the principal or supporting funder of the research presented here. We hope you enjoyed reading this issue. Please send any questions or feedback to: **links@tfri.ca**

Previous issues are available online in our E-Newsletter Archive.

Visit www.tfri.ca *to learn more about our research investment portfolio*

TFRI is either the principal or supporting funder of the research presented here. Funded investigators are invited to submit their publications to us for consideration in an upcoming issue.